Praxis Precision Medicines (PRAX) on Monday filed a registration statement with the US Securities and Exchange Commission for the potential sale of securities from time to time in one or more offerings.

The filing covers, common stock, preferred stock, debt securities, warrants and units.

The company also filed a supplement prospectus for the offer and sale of common stock up to $250 million under an open market sale agreement.

The company plans to use the net proceeds to fund research, develop product candidates, for working capital and other general corporate purposes.